CN101160354B - 高分子型癌症治疗用药及其制造方法 - Google Patents

高分子型癌症治疗用药及其制造方法 Download PDF

Info

Publication number
CN101160354B
CN101160354B CN2006800123378A CN200680012337A CN101160354B CN 101160354 B CN101160354 B CN 101160354B CN 2006800123378 A CN2006800123378 A CN 2006800123378A CN 200680012337 A CN200680012337 A CN 200680012337A CN 101160354 B CN101160354 B CN 101160354B
Authority
CN
China
Prior art keywords
sma
metalloporphyrin
micelle
znpp
micelle complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800123378A
Other languages
English (en)
Chinese (zh)
Other versions
CN101160354A (zh
Inventor
前田浩
卡雷德·具礼志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN101160354A publication Critical patent/CN101160354A/zh
Application granted granted Critical
Publication of CN101160354B publication Critical patent/CN101160354B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/42—Introducing metal atoms or metal-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/04—Anhydrides, e.g. cyclic anhydrides
    • C08F222/06—Maleic anhydride
    • C08F222/08—Maleic anhydride with vinyl aromatic monomers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0091—Complexes with metal-heteroatom-bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN2006800123378A 2005-04-18 2006-04-13 高分子型癌症治疗用药及其制造方法 Expired - Fee Related CN101160354B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005120159 2005-04-18
JP120159/2005 2005-04-18
PCT/JP2006/307852 WO2006112361A1 (ja) 2005-04-18 2006-04-13 高分子型癌治療用医薬およびその製造方法

Publications (2)

Publication Number Publication Date
CN101160354A CN101160354A (zh) 2008-04-09
CN101160354B true CN101160354B (zh) 2010-12-29

Family

ID=37115084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800123378A Expired - Fee Related CN101160354B (zh) 2005-04-18 2006-04-13 高分子型癌症治疗用药及其制造方法

Country Status (9)

Country Link
US (1) US8128959B2 (enExample)
EP (1) EP1873204B1 (enExample)
JP (2) JPWO2006112362A1 (enExample)
KR (1) KR101165760B1 (enExample)
CN (1) CN101160354B (enExample)
AU (1) AU2006238072A1 (enExample)
CA (1) CA2605205C (enExample)
TW (2) TW200722095A (enExample)
WO (2) WO2006112361A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102000070B (zh) * 2009-07-08 2012-05-23 山东弘立医学动物实验研究有限公司 用于治疗肿瘤的锰卟啉-氯尼达明联合用药物
HUE032791T2 (en) * 2011-09-05 2017-11-28 Hiroshi Maeda Polymer-type fluorescent molecule probe
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
EP3072910A4 (en) 2013-11-19 2018-02-21 Hiroshi Maeda Derivative of styrene-maleic acid copolymer
AU2015210650A1 (en) * 2014-02-03 2016-08-18 Cecilia ESPADAS Formulations for microparticle delivery of zinc protoporphyrins
US10232050B1 (en) 2014-12-12 2019-03-19 Clemson University Multi-functional particles and methods of using the same
US11633355B2 (en) 2014-12-12 2023-04-25 Clemson University Research Foundation Multi-functional particles and methods of using the same
US20200222564A1 (en) * 2019-01-15 2020-07-16 Tianjin University Compound Amphiphilic Peptide Nanomicelle, Preparation and Use Thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6017206B2 (ja) * 1977-03-24 1985-05-01 浩 前田 ネオカルチノスタチン誘導体の製造法
EP0087957B1 (en) * 1982-02-27 1986-11-26 Kuraray Co., Ltd. Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component
JPS58149903A (ja) * 1982-02-27 1983-09-06 Kuraray Co Ltd ネオカルチノスタチン複合体の製造法
JPH0630628B2 (ja) * 1987-12-16 1994-04-27 キング醸造株式会社 生細胞数及び活力の測定方法
JP3191223B2 (ja) 1991-10-04 2001-07-23 株式会社光ケミカル研究所 ポルフィリン誘導体とその用途
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
JPH0680671A (ja) 1992-09-03 1994-03-22 Toyo Hatsuka Kogyo Kk ポルフィリン二量体とその用途
JPH07330773A (ja) 1994-06-07 1995-12-19 Toyo Hatsuka Kogyo Kk ポルフィリン誘導体とその用途
JPH1160499A (ja) * 1997-08-22 1999-03-02 Hiroshi Maeda 抗腫瘍剤
JPH11335267A (ja) * 1998-05-27 1999-12-07 Nano Career Kk 水難溶性薬物を含有するポリマーミセル系
JP4291973B2 (ja) * 2001-02-08 2009-07-08 大阪瓦斯株式会社 光電変換材料および光電池
JP3615721B2 (ja) * 2001-07-13 2005-02-02 ナノキャリア株式会社 薬物含有高分子ミセルの製造方法
JP5000050B2 (ja) 2001-08-31 2012-08-15 浩 前田 抗腫瘍剤及びその製造方法
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
CA2489259C (en) 2003-05-26 2011-08-30 Hiroshi Maeda Polymeric micelle complexes of low molecular weight antitumor agents and styrene maleic acid copolymers
JP2005029480A (ja) * 2003-07-08 2005-02-03 Nano Career Kk ピルビニウムを内包した高分子ミセルを含有する抗癌剤
GB0415663D0 (en) * 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Khaled Greish et al..Copoly(styrene-maleic acid)-Pirarubicin Micelles:High Tumor-Targeting Efficiency with Little Toxicity.《Bioconjugate Chem.》.2004,第16卷(第1期),230-236. *

Also Published As

Publication number Publication date
EP1873204B1 (en) 2011-09-21
WO2006112362A1 (ja) 2006-10-26
TWI374742B (enExample) 2012-10-21
TW200719904A (en) 2007-06-01
JP4522452B2 (ja) 2010-08-11
AU2006238072A1 (en) 2006-10-26
CA2605205C (en) 2011-11-01
TW200722095A (en) 2007-06-16
KR101165760B1 (ko) 2012-07-18
JPWO2006112362A1 (ja) 2008-12-11
WO2006112361A1 (ja) 2006-10-26
US20090062476A1 (en) 2009-03-05
JPWO2006112361A1 (ja) 2008-12-11
EP1873204A4 (en) 2009-03-25
CN101160354A (zh) 2008-04-09
US8128959B2 (en) 2012-03-06
KR20080002814A (ko) 2008-01-04
EP1873204A1 (en) 2008-01-02
CA2605205A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
Moreno‐Alcántar et al. Gold complexes in anticancer therapy: from new design principles to particle‐based delivery systems
Wang et al. High co-loading capacity and stimuli-responsive release based on cascade reaction of self-destructive polymer for improved chemo-photodynamic therapy
Lu et al. Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy
Li et al. Singlet oxygen-responsive micelles for enhanced photodynamic therapy
Xiao et al. Photosensitive Pt (IV)–azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo
Zhang et al. Redox-hypersensitive organic nanoparticles for selective treatment of cancer cells
Iyer et al. High-loading nanosized micelles of copoly (styrene–maleic acid)–zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor
Liu et al. Ce6 nanoassemblies: molecular mechanism and strategies for combinational anticancer therapy: special collection: aggregation‐induced processes and functions
JP2025137881A (ja) ボロン酸エステルプロドラッグおよびそれらの使用
Karges Encapsulation of Ru (II) polypyridine complexes for tumor-targeted anticancer therapy
JP2022552416A (ja) ブラシプロドラッグおよびその使用
WO2012089768A1 (en) System for the release of a therapeutic agent, pharmaceutical compositions containing it, the preparation and medical use thereof
Wu et al. Hydrogen-bond-driven core-crosslinked supramolecular micelles with pH/thermal/glutathione-responsive drug release toward enhanced cancer therapy
Liu et al. Linear-dendritic polymer-platinum complexes forming well-defined nanocapsules for acid-responsive drug delivery
Yang et al. Bone-targeted calcium phosphate-polymer hybrid nanoparticle co-deliver zoledronate and docetaxel to treat bone metastasis of prostate cancer
Liu et al. Platinum-containing supramolecular drug self-delivery nanomicelles for efficient synergistic combination chemotherapy
Cao et al. How the Versatile Self‐Assembly in Drug Delivery System to Afford Multimodal Cancer Therapy?
CN111420068B (zh) 聚乙二醇-树枝状聚赖氨酸/酸酐-顺铂复合物及其制备方法和应用
Lan et al. CD44-targeted photoactivatable polymeric nanosystem with on-demand drug release as a “photoactivatable bomb” for combined photodynamic therapy–chemotherapy of cancer
CN113384698B (zh) 一种协同化疗/声-光动力治疗的自组装纳米药物及其应用
Santos et al. Platinum-based chemotherapy: trends in organic nanodelivery systems
KR20230141306A (ko) 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물
CN101160354A (zh) 高分子型癌症治疗用药及其制造方法
EP2978428A1 (en) Stable nanocomposition comprising epirubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
CN219208188U (zh) 一种基于光动力驱动细胞质膜激活的抗肿瘤靶向纳米药物递送控释系统

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101229

Termination date: 20180413

CF01 Termination of patent right due to non-payment of annual fee